Phase 3Completed

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin

Sponsor
AstraZeneca (Industry)
Enrollment
455 enrolled
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, 5 mg + insulin; Placebo + insulin
Ages
adults, older adults
Registry
NCT00757588

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.

Primary outcomes

  • Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF])

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered